This Phase 2 trial enrolls participants who meet DSM-5 criteria for moderate to severe AUD and tracks changes in heavy drinking days, total alcohol consumption, and self-reported craving intensity over a 24-week treatment period
By the end of the 1960s it was clear that there were a number of peptide substances with similar biological properties to glucagon present along the entire length of the intestine, from the duodenum to the rectum
9 The consensus statement from the American Association of Clinical Endocrinologists supports the use of GLP-1 RAs as first-line therapy in managing hyperglycaemia in T2D patients with established (or at high risk of) atherosclerotic CVD, as well as in those with chronic kidney disease or a history of stroke or transient ischaemic attack, while recommending the administration of sodiumglucose cotransporter 2 inhibitors to HF patients
Regardless, you can imagine using a patients genetics to identify which drugs they would respond best to, and this information would more precisely set their expectations and make them more willing to persist with treatment, which is a great way to boost retention (and adherence)
These are preclinical research observations only
